Oral STAT3 Inhibitor, TTI-101, in Patients with Advance Cancers

Actively Recruiting

Inhibition of STAT3 in cancer has been shown to inhibit tumorigenesis as well as reverse immunosuppression within the tumor microenvironment. TTI-101 is currently being studied at MD Anderson Cancer Center in a first-in-man Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy.

For more information about the ongoing trial of TTI-101 being conducted at MD Anderson, please visit ClinicalTrials.gov (NCT03195699)

Expanded Access to Investigational, Unapproved Medicines
We believe that our fastest path to fulfill our commitment to patients is to focus on working with the FDA to complete the required clinical studies needed to demonstrate safety and effectiveness of our investigational therapy TTI-101 for multiple cancer indications. This focus on completing our clinical trials will help us expeditiously achieve the best outcome for the greatest number of patients suffering from cancer.

Currently, Tvardi Therapeutics does not have an Expanded Access Program for any advanced cancers. We encourage patients to discuss their treatment options, including clinical trials, with their medical team.